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Abstract
Nosocomial transmission of multiresistant bacteria is a growing healthcare issue. In addition,
new pathogens and pathogenic mechanisms, associated with therapies based on the use of live
microorganisms, can be of importance in the near future. The current issue of CKJ illustrates
healthcare-associated infections that go beyond common bacteria. First, the therapeutic use of
live BCG mycobacteria is not without risks in the chronic kidney disease patients. Familiarity with
these complications will allow their rapid recognition and optimized management. Second, strict
adherence to universal precautions and healthcare guidelines is still mandatory in order to avoid
undesirable risks such as transmission of hepatitis B virus.
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Since the early days of medicine, infection associated with
medical procedures has been a constant companion.
Throughout the 19th century, the discovery of microor-
ganisms and their importance in infection led to the intro-
duction of practices aimed at minimizing the risk of
infection, notably the introduction of antisepsis by Lister,
and the description of the importance of handwashing by
Semmelweis. These measures, together with the introduc-
tion of antibiotics and vaccines, achieved a dramatic de-
crease of healthcare-associated infections during the last
decades of the 20th century. However, new problems ap-
peared, as organisms became antibiotic-resistant and
multidrug-resistance spread throughout the world [1]. The
ﬁght against antibiotic-resistant organisms rediscovered
the importance of classical universal measures to prevent
their spread, notably the use of handwashing as the key
procedure in all protocols [2]. However, in recent years, the
introduction of new therapeutic procedures, and the rec-
ognition of the importance of non-bacterial pathogens as
a cause of healthcare-associated infections, has both gen-
erated new challenges and reminded of the need for uni-
versal precautions.
In this issue, Kliner et al. [3] report a case of hepatitis B
virus contagion in an inpatient renal ward. Hepatitis B has
been considered a major risk among haemodialysis pa-
tients and healthcare workers since the early times of the
technique. Recommendations and guidelines stress pre-
ventive measures in dialysis units [4–7], including serologic-
al testing before starting chronic dialysis and monitoring
thereafter, vaccination of all patients and healthcare per-
sonnel, physical separation of hepatitis B virus dialysis
monitors and universal precautions. Vaccination is currently
recommended for all chronic kidney disease patients [7]
and has a rate of protection higher than 70% [4]. However,
it should be reminded that a high vaccine dose is required,
as well as annual post-vaccination serology follow-up and
booster vaccinations if needed. In the case of infection,
serological markers become positive a few weeks after con-
tagion. The published case illustrates the need for a full epi-
demiological work-up in the case a recent hepatitis B
infection is diagnosed. Thus, careful research following a
new case of hepatitis B virus infection uncovered many fail-
ures, including poor vaccination status of patients and
many violations of universal infection control measures,
such as poor hand hygiene and visible contamination of
blood glucose testing equipment [3]. It was concluded that
patient-to-patient transmission was likely to have occurred
on the renal ward due to multiple failures in infection
control. The lesson to be learned is that, despite the exist-
ence of an effective vaccine, no relaxation with universal
precautions should be allowed, because a false safety sen-
sation can lead to a potential disaster. In this regard, po-
tential transmission of hepatitis B virus is not limited to
haemodialysis units. Since there is no vaccine for other
blood-transmitted diseases, such as HIV or hepatitis C,
strict adherence to universally recommended measures
must be mandatory in the management of all patients
even for those immune to hepatitis B virus [6].
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Clin Kidney J (2015) 8: 100–101
doi: 10.1093/ckj/sfu143
Iqbal et al. [8] illustrate another uncommon cause of
healthcare-associated infection, the development of in-
fection secondary to the use of a live microorganism
(Mycobacterium bovis BCG strain) as an immunomodulator
for the treatment of bladder carcinoma. Mycobacterium
bovis BCG was originally developed as a vaccine against
tuberculosis, but has been used recently as an inducer of
an inﬂammatory response that leads to destruction of
bladder cancer cells. Since M. bovis BCG is a live—although
attenuated—organism, there is always a risk of develop-
ment of a disease that can be as severe as disseminated
tuberculosis [9]. To treat BCG infections, it should be re-
membered that, like all M. bovis strains, BCG is always
resistant to pyrazinamide, but susceptible to all other
ﬁrst-line antituberculous drugs. The peritoneum is a site
of mycobacterial infection in peritoneal dialysis patients
[10]. Tuberculous peritonitis may present as repeated peri-
tonitis episodes in which usual peritonitis-inducing bacteria
may grow, thus delaying the diagnosis. This is troublesome
since late diagnosis and therapy is associated with
adverse outcomes, including death. This preference of
mycobacterial infection or reactivation for the peritoneal
cavity points to a local immune deﬁcient state. Indeed,
components of peritoneal dialysis solutions, such as the
glucose degradation product 3,4-dideoxyglucosone-3-ene
(3,4-DGE), promote death and dysfunction of leukocytes
[11–14]. Indeed, 3,4-DGE was originally described as an
immune suppressant derived from seaweed [15]. Periton-
eal dialysis patients also develop bioﬁlms over the periton-
eal dialysis catheter. Bioﬁlms may impact the efﬁcacy of
therapy, since they increases the antimicrobial resistance
of the embedded organisms. Although bioﬁlm has a
minor role in mycobacterial infection, the relevance of this
pathogenic mechanism will increase in the near future,
because of the increasing number of patients with im-
plants and biomaterials [16, 17].
This healthcare-associated infection opens the ﬁeld
of problems associated with the use of live organisms
as part of the treatments for different diseases, even
infections. Research into the use of probiotics and/or
live intestinal microbiota to treat conditions such as
Clostridium difﬁcile-associated diarrhoea [18] is likely to
grow. Thus, recent research emphasizes the importance
of gut organisms in the development of different dis-
eases [19–21], and this issue may be approached
through live bacteria therapy. These procedures may
lead to the development of infectious complications,
as it is the case with the BCG strain, so we should be
prepared to identify and correct them early in order to
avoid more severe problems.
The ﬁght against healthcare-associated infection is an
endless one. In this sense, the development of new thera-
peutic and diagnostic procedures (some of them involving
the use of live microorganisms) will be followed by the de-
scription of infectious complications. As they are described,
dissemination of knowledge about these complications
may allow early identiﬁcation, implementation of pre-
emptive measures and therapy that limits morbidity and
mortality. Until then, remember to wash your hands fre-
quently and disinfect potentially blood-stained surfaces,
because these are still the main and most important mea-
sures to ﬁght healthcare-associated infections.
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(See related article by Kliner et al. Identiﬁcation, investiga-
tion and management of patient-to-patient hepatitis
B transmission within an inpatient renal ward in North
West England. Clin Kidney J (2015) 8: 102–106.)
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